Novo Nordisk: stock jumps; a broker notes group confirmation

(CercleFinance.com) - The Novo Nordisk share is jumping almost 5% today, while an analyst at Oddo BHF, although maintaining his "neutral" recommendation on the share, noted a number of confirmations made by the company at the ADA congress.


This conference was an opportunity to review the results of oral semaglutide and to confirm its potential in its class. However, Novo Nordisk presented additional results on the PIONEER 2 study, sema oral vs empagliflozin (SGLT2) and PIONEER 4 (vs Victoza). The broker considers that the results at 52 weeks confirm those observed at 26 weeks, i.e. a statistically significant improvement vs empagliflozin and non-inferiority vs Victoza. Weight loss also improves with time, the broker appreciates.

Oddo BHF maintains its target price of 333 Danish Kronor, meaning upside potential of 3%.



Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.